Figure 3

Association of FASN and HER2 in breast cancer cells. SKBR3 (A) and BT474 (B) cells were treated for one hour with: 1) no agent (control); 2) 50 ng/mL HRG; 3) 1 μM lapatinib or 4) 50 ng/mL HRG plus 1 μM lapatinib. The immunoprecipitated FASN complexes were subjected to Western blotting for FASN, HER2 and PT66. (C) Whole-cell lysates from SKBR3 (left panel) and BT474 cells (right panel) were subjected to Western blotting for pHER2 (Y1248), pHER3 (Y1289), pAkt (S473), pErk1/2, HER2, HER3, Akt, Erk1/2, FASN and β-actin.